Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Transtocation with Adnexal Metastasis

被引：0
|
作者：
Wang, Wenxian [1 ]
Jin, Ying [1 ]
Zhang, Yiping [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Ovarian metastasis; non-small cell lung cancer; ALK; Crizotinib;
D O I：
10.1016/j.jtho.2016.11.1654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02a-024
引用
收藏
页码：S1176 / S1176
页数：1
相关论文
共 50 条
  • [21] Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
    Xu, X.
    Li, N.
    Fan, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445
  • [22] EML4-ALK MONITORING OF CRIZOTINIB RESPONSE IN BLOOD PLATELETS AND PLASMA OF NSCLC PATIENTS
    Nilsson, Jonas
    Costa, Carlota
    Karachaliou, Niki
    Taron, Miquel
    Tannous, Bakhos
    Thunnissen, Erik
    Wurdinger, Thomas
    Rosell, Rafael
    Smit, Egbert
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S804 - S804
  • [23] Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report
    Wu, Xueqian
    Wang, Weiya
    Zou, Bingwen
    Li, Yanying
    Yang, Xiaojuan
    Liu, Ning
    Ma, Qizhi
    Zhang, Xiaoxuan
    Wang, Yongsheng
    Li, Dan
    [J]. THORACIC CANCER, 2020, 11 (06) : 1695 - 1698
  • [24] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Bilgin, Burak
    Sendur, Mehmet Ali Nahit
    Yucel, Sebnem
    Hizal, Mutlu
    Guner, Gurkan
    Akyurek, Nalan
    Erol, Cihan
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    Kilickap, Sadettin
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2637 - 2643
  • [25] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Burak Bilgin
    Mehmet Ali Nahit Şendur
    Şebnem Yücel
    Mutlu Hizal
    Gürkan Güner
    Nalan Akyürek
    Cihan Erol
    Muhammed Bülent Akıncı
    Didem Şener Dede
    Bülent Yalçın
    Sadettin Kılıçkap
    [J]. Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2637 - 2643
  • [26] Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant
    To, Ka-Fai
    Tong, Joanna H. M.
    Yeung, King S. F.
    Lung, Raymond W. M.
    Law, Peggy P. Y.
    Chau, Shuk Ling
    Kang, Wei
    Tong, Carol Y. K.
    Chow, Chit
    Chan, Anthony W. H.
    Leung, Linda K. S.
    Mok, Tony S. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) : 883 - 891
  • [27] EML4-ALK Fusion in Lung Reply
    Falini, Brunangelo
    Martelli, Maria Paola
    Pileri, Stefano A.
    Sozzi, Gabriella
    Gasparini, Patrizia
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2010, 176 (03): : 1553 - 1554
  • [28] Clinical effect of crizotinib on lung cancer patients with EML4-ALK fusion gene mutation
    Wang, Zhiyong
    Wang, Wei
    Kong, Xiaodong
    Li, Guangxu
    Yang, Weiwei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (09): : 11632 - 11638
  • [29] Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer
    Dai, Ying
    Wei, Quanxiang
    Schwager, Christian
    Moustafa, Mahmoud
    Zhou, Cheng
    Lipson, Kenneth E.
    Weichert, Wilko
    Debus, Juergen
    Abdollahi, Amir
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 114 (02) : 173 - 181
  • [30] Clinical outcome study of crizotinib in IHC proven EML4-ALK fusion gene among Indian patients with adenocarcinoma lung
    Batra, U.
    Sharma, M.
    Jain, A.
    Agarwal, M.
    Goyal, P.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345